Kanbay ADDIN EN.CITE Endothelial Placebo/no 0.20 (-0.20, 2014 General Allopurinol independent dilatation 5 216 113 MD Fixed treatment 0.61) (%) Mortality Infants with Placebo/no Death during neonatal Chaudhari64 2012 Allopurinol 3 114 58 RR Fixed 0.88 (0.56, 1.38) ischaemic treatment or infancy encephalopathy Infants with Placebo/no Death during neonatal Chaudhari64 2012 Allopurinol 2 41 20 RR Fixed 0.97 (0.62, 1.51) treatment or infancy encephalopathy Infants with Death or serve Placebo/no Chaudhari64 2012 Allopurinol neurodevelopmental 3 110 56 RR Fixed 0.78 (0.56, 1.08) treatment disability in survivors encephalopathy Infants with Death or serve Placebo/no Chaudhari64 2012 Allopurinol neurodevelopmental 2 41 20 RR Fixed 0.92 (0.66, 1.30) treatment disability in survivors encephalopathy Other outcomes Infants with Placebo/no Severe quadriplegia in Chaudhari64 2012 Allopurinol 3 73 38 RR Fixed 0.59 (0.28, 1.27) treatment surviving infants encephalopathy
Kanbay ADDIN EN.CITE 2014 General Allopurinol Placebo/no treatment Endothelial independent dilatation (%) 5 216 113 MD Fixed 0.20 (-0.20, 0.61) Mortality Chaudhari64 2012 Infants with encephalopathy Allopurinol Placebo/no treatment Death during neonatal or infancy 3 114 58 RR Fixed 0.88 (0.56, 1.38) Chaudhari64 2012 Infants with encephalopathy Allopurinol Placebo/no treatment Death during neonatal or infancy 2 41 20 RR Fixed 0.97 (0.62, 1.51) Chaudhari64 2012 Infants with encephalopathy Allopurinol Placebo/no treatment Death or serve neurodevelopmental disability in survivors 3 110 56 RR Fixed 0.78 (0.56, 1.08) Chaudhari64 2012 Infants with encephalopathy Allopurinol Placebo/no treatment Death or serve neurodevelopmental disability in survivors 2 41 20 RR Fixed 0.92 (0.66, 1.30) Other outcomes Chaudhari64 2012 Infants with encephalopathy Allopurinol Placebo/no treatment Severe quadriplegia in surviving infants 3 73 38 RR Fixed 0.59 (0.28, 1.27) ischaemic